Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03391934 | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | unknown | Phase 3 | 234 | CinnagenINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 |
| clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05325528 | Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases | unknown | Phase 2 / Phase 3 | 40 | Zhejiang UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04222114 | Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis | unknown | Phase 3 | 282 | LintonPharm Co.,Ltd.INDUSTRY | 3 | Jan 31, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05698082 | FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | unknown | Phase 2 / Phase 3 | 120 | xiaoliang HuangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02773485 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | unknown | Phase 3 | 155 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05429697 | Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer | unknown | Phase 2 / Phase 3 | 128 | SMT bio Co., Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05544253 | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC | unknown | Phase 2 / Phase 3 | 68 | West China HospitalOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05540951 | VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer | unknown | Phase 3 | 78 | Fudan UniversityOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05487443 | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | unknown | Phase 2 / Phase 3 | 50 | First People's Hospital of HangzhouOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04931381 | Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | unknown | Phase 3 | 100 | Changhai HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04931394 | Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer | unknown | Phase 3 | 200 | Changhai HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05472896 | TACE With Dicycloplatin(TP21) in Unresectable HCC | unknown | Phase 3 | 332 | Gao-jun TengOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT04401709 | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer | unknown | Phase 3 | 490 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05409417 | Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04139135 | A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | unknown | Phase 3 | 642 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05231382 | Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma | unknown | Phase 3 | 426 | Sun Yat-sen UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05220020 | TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | unknown | Phase 3 | 299 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05378867 | A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC(CRC) | unknown | Phase 3 | 126 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 0 | May 18, 2022 | clinicaltrials |
| NCT05374252 | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients | unknown | Phase 3 | 102 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT05362617 | mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy | unknown | Phase 3 | 328 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05327751 | Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer(HFS) | unknown | Phase 3 | 44 | Tanta UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03957733 | Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients. | unknown | Phase 2 / Phase 3 | 338 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05178628 | The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer(imPaCT-PRO) | unknown | Phase 3 | 450 | Michalis KaramouzisOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02192671 | HR Versus RFA for HCC in Patients With PHT(HR-HCC/PHT) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT03988998 | Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma | unknown | Phase 3 | 100 | Guangxi Medical UniversityOTHER | 0 | Jan 18, 2022 | clinicaltrials |
| NCT05187481 | Effect of Jianpi Huatan Decoction on Advanced Colorectal Cancer | unknown | Phase 3 | 200 | Xiyuan Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03801668 | Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | unknown | Phase 3 | 294 | Huazhong University of Science and TechnologyOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT03338647 | SBRT or TACE for Advanced HCC | unknown | Phase 3 | 180 | University of AarhusOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT05079438 | Dendrobium Huoshanense Suppository in Rectal Cancer | unknown | Phase 3 | 168 | Zhejiang Cancer HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT05074966 | The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts | unknown | Phase 3 | 314 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT04781270 | mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases | unknown | Phase 3 | 308 | Fudan UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT05056337 | Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | unknown | Phase 3 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | unknown | Phase 3 | 234 | Feng WangOTHER | 0 | Sep 20, 2021 | clinicaltrials |
| NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02934464 | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers(ARMANI) | unknown | Phase 3 | 280 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 13, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Apr 5, 2023source: clinicaltrials